Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Sep;14(7):101581.
doi: 10.1016/j.jgo.2023.101581. Epub 2023 Jul 6.

Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England: A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset

Sophie Pilleron  1 , Eva J A Morris  2 , David Dodwell  3 , Kevin N Franks  4
Affiliations
Observational Study

Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England: A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset

Sophie Pilleron et al. J Geriatr Oncol. 2023 Sep.

Abstract

Introduction: We described the patterns of chemotherapy use and outcomes in patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC) by age in England.

Materials and methods: In this retrospective population-based study, we included 20,716 (62% stage IV) patients with NSCLC diagnosed from 2014 to 2017 treated with chemotherapy. We used the Systemic Anti-Cancer Treatment (SACT) dataset to describe changes in treatment plan and estimated 30 and 90-day mortality rates and median, 6-, and 12-month overall survival (OS) using Kaplan Meier estimator for patients aged <75 and ≥ 75 by stage. Using flexible hazard regression models we assessed the impact of age, stage, treatment intent (stage III), and performance status on survival.

Results: Patients aged ≥75 years were less likely to receive two or more regimens, more likely to have their treatment modified because of comorbidities and their doses reduced compared to younger patients. However, early mortality rates and overall survival were similar across ages, apart from the oldest patients with stage III disease.

Discussion: This observational study demonstrates that age is associated with treatment patterns in an older population with advanced NSCLC in England. Although this reflects a pre-immunotherapy period, given the median age of NSCLC patients and increasingly older population, these results suggest older patients (>75 yrs) may benefit from more intense treatments.

Keywords: Epidemiology; Geriatric oncology; Non-small cell lung cancer; Population-based; Survival.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest SP, EJAM, DD do not have any conflict to report. KNF reports the following: Active research funding/grant: Honoraria/Advisory Boards: AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Meyers-Squibb, Lilly, Roche and Takeda.

Figures

Fig. 1
Fig. 1. Flow chart.
Fig. 2
Fig. 2
Overall survival (OS) over the initial year of the initiation of chemotherapy at ages 50, 60, 70, and 80; (B) 6 and 12-month OS by age at diagnosis, and (C) 6-month OS by age and performance status in patients diagnosed with stage III and IV non-small cell lung cancer in 2014–2017 and treated with chemotherapy (Note. Solid lines represent overall survival estimates and dashed lines represent 95% confidence intervals).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Araghi M, et al. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 study. Thorax. 2021 - PubMed
    1. Araghi M, et al. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project) Gut. 2020 - PubMed
    1. NICE. Lung cancer: diagnosis and management - NICE guideline [NG122] 2021. https://www.nice.org.uk/guidance/ng122 .
    1. Sedrak MS, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71:78–92. doi: 10.3322/caac.21638. - DOI - PMC - PubMed
    1. Mohile SG, et al. Practical assessment and Management of Vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:2326–47. doi: 10.1200/JCO.2018.78.8687. - DOI - PMC - PubMed

Publication types